Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An extranodal non-Hodgkin lymphoma that arises from the stomach with the bulk of the mass located in the stomach. The vast majority of cases are diffuse large B-cell lymphomas and B-cell lymphomas of the mucosa-associated lymphoid tissue.
Biomarker and diagnostic research for gastric non-hodgkin lymphoma has been reported in the published literature.
No clinical trials have been registered for gastric non-hodgkin lymphoma.
125 publications have been identified in PubMed for gastric non-hodgkin lymphoma. Research spans Case Report / Case Series (43%), Epidemiology / Natural History (24%), and Clinical Trial Publication (12%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 54 | 43% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 5:48 PM UTC
Genetic and Rare Diseases Info Center
Disease patterns and progression
30 |
24% |
Clinical study results | 15 | 12% |
Research summaries | 8 | 6% |
Laboratory research | 8 | 6% |
Testing and diagnosis research | 7 | 6% |
New treatment approaches | 3 | 2% |
Aune D (2026). [PMID: 41879966](https://pubmed.ncbi.nlm.nih.gov/41879966/). *Eur J Epidemiol*. [Epidemiology / Natural History]
Buja A (2026). [PMID: 40818023](https://pubmed.ncbi.nlm.nih.gov/40818023/). *International journal of cancer*. [Epidemiology / Natural History]
Moriwaki K (2026). [PMID: 41922227](https://pubmed.ncbi.nlm.nih.gov/41922227/). *J Clin Exp Hematop*. [Case Report / Case Series]
Yu S (2026). [PMID: 41780126](https://pubmed.ncbi.nlm.nih.gov/41780126/). *Clin Oncol (R Coll Radiol)*. [Epidemiology / Natural History]
Kurashige M (2026). [PMID: 41565277](https://pubmed.ncbi.nlm.nih.gov/41565277/). *J Clin Exp Hematop*. [Case Report / Case Series]
Qiaochu L (2026). [PMID: 41668558](https://pubmed.ncbi.nlm.nih.gov/41668558/). *Hematology (Amsterdam, Netherlands)*. [Epidemiology / Natural History]
Bendor CD (2026). [PMID: 41552005](https://pubmed.ncbi.nlm.nih.gov/41552005/). *EClinicalMedicine*. [Basic Science / Preclinical]
Suzuki K (2026). [PMID: 41954337](https://pubmed.ncbi.nlm.nih.gov/41954337/). *Cancer*. [Epidemiology / Natural History]
Ben Ismail I (2026). [PMID: 41837111](https://pubmed.ncbi.nlm.nih.gov/41837111/). *International journal of surgery case reports*. [Clinical Trial Publication]
Ahn JY (2026). [PMID: 41430211](https://pubmed.ncbi.nlm.nih.gov/41430211/). *The Korean journal of internal medicine*. [Epidemiology / Natural History]
AI-curated news mentioning gastric non-hodgkin lymphoma
Updated Sep 5, 2026
A case report highlights a rare instance of dural follicular non-Hodgkin lymphoma presenting as a chronic subdural hematoma. This finding contributes to the understanding of atypical presentations of lymphomas and may aid in differential diagnosis.
Legend Biotech's in vivo CAR T therapy shows promising results with all six non-Hodgkin lymphoma patients responding to treatment. This success positions the company as a potential acquisition target, according to analysts at Oppenheimer.
Recent research highlights new investigational agents targeting cutaneous T-cell lymphoma within the broader category of non-Hodgkin lymphoma. These developments may offer novel therapeutic options for patients suffering from this rare condition.
A recent study explores the endoscopic characteristics of primary gastric lymphoma, providing insights that may help predict treatment response. This research could enhance diagnostic accuracy and therapeutic strategies for affected patients.
ModeX Therapeutics is advancing MDX2003, a tetraspecific therapy for non-Hodgkin lymphoma, aiming for improved efficacy and safety. The therapy is currently in phase 1 trials and is designed for community clinic use through intravenous administration.